Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

4 results

  • 37 - Interventional Treatment Methods for Unresectable Lung Tumors

  • from PART III - ORGAN-SPECIFIC CANCERS
    • By Thomas J. Vogl, Professor, Department of Diagnostic and Interventional Radiology University of Frankfurt Frankfurt, Germany, Stefan Zangos, Radiologist, University of Frankfurt Frankfurt, Germany, Christopher Herzog, Assistant Professor of Radiology, University of Frankfurt Frankfurt, Germany, Sebastian Lindemayr, Radiologist, University of Frankfurt Frankfurt, Germany
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book:
    Interventional Oncology
    Published online:
    18 May 2010
    Print publication:
    15 September 2008, pp 475-482

  • Summary

    Malignant lung diseases are a major topic in community health. The incidence for lung cancer rapidly increased in the last century (1), and today it is the most common malignant disease worldwide. In the United States, bronchial carcinoma is the leading malignant disease for both genders, and in 2000, the incidence was 164,000 with a morbidity of 157,000 (2). Pulmonary metastases are also a challenge and occur in patients with a variety of cancers. Between 20% and 30% of patients afflicted with cancer generate pulmonary metastases (3).

    The prognoses for bronchial carcinomas and metastases remain poor. Resection of stage I and II carcinomas offers the best chance in long-term survival (4–7), but only 25% to 30% of these tumors are resectable (4–6). Survival rates for bronchial carcinomas and pulmonary metastases are similar, with a mean survival for all bronchial carcinomas of 12 months (4) and a mean survival after diagnosis of non-resectable lung metastases of less than 1 year (8). Five-year survival rates of 10% for all bronchial carcinomas (5) have been reported, with a mean 5-year survival rate of 23% to 50% after resection (4, 9–11) and 1% (4) for unresectable carcinomas. In patients with lung metastases who undergo pulmonary resection, a 5-year survival rate of 20% to 46% (12–19) has been reported.

    As an alternative to resection or as a neoadjuvant therapeutic option, various therapies such as radiotherapy or chemotherapy have been developed (1), and in particular, systemic chemotherapy has shown encouraging results (16, 20).